Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Foghorn Therapeutics Inc. - Common Stock
(NQ:
FHTX
)
4.820
-0.270 (-5.30%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Foghorn Therapeutics Inc. - Common Stock
< Previous
1
2
3
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 16, 2024
Via
Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
December 16, 2024
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program.
Via
Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 19, 2024
Via
Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
August 19, 2024
Via
Benzinga
Foghorn Therapeutics: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
What 5 Analyst Ratings Have To Say About Foghorn Therapeutics
August 07, 2023
Via
Benzinga
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 06, 2024
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 07, 2024
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
February 08, 2024
Via
Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
February 08, 2024
Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development.
Via
Benzinga
Analyst Ratings for Foghorn Therapeutics
June 28, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Foghorn Therapeutics
June 08, 2023
Via
Benzinga
Analyst Expectations for Foghorn Therapeutics's Future
April 25, 2023
Via
Benzinga
Expert Ratings for Foghorn Therapeutics
March 28, 2023
Via
Benzinga
Foghorn Therapeutics Earnings Perspective: Return On Capital Employed
March 15, 2023
Via
Benzinga
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 30, 2023
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...
Via
Benzinga
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
June 29, 2023
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market...
Via
Benzinga
Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
June 28, 2023
Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 20, 2022
Thursday saw 177 companies set new 52-week lows.
Via
Benzinga
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results
April 24, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16....
Via
Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 24, 2023
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.
Via
Benzinga
US Stocks Turn Lower; Nasdaq Dips 100 Points
April 24, 2023
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P...
Via
Benzinga
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
April 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 24, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
March 28, 2023
Via
Benzinga
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
February 16, 2023
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
November 30, 2022
During Wednesday's session, 107 stocks hit new 52-week lows.
Via
Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
September 30, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.